<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1757">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05138289</url>
  </required_header>
  <id_info>
    <org_study_id>CP- 908-001</org_study_id>
    <nct_id>NCT05138289</nct_id>
  </id_info>
  <brief_title>The REVEALPLAQUE Study: A pRospEctiVe, multicEnter Study to AnaLyze PLAQUE Using CCTA</brief_title>
  <acronym>REVEALPLAQUE</acronym>
  <official_title>The REVEALPLAQUE Study: A pRospEctiVe, multicEnter Study to AnaLyze PLAQUE Using CCTA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HeartFlow, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HeartFlow, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the level of agreement between noninvasive CCTA-based quantification&#xD;
      and characterization of coronary atherosclerosis and invasive IVUS .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center study. All patients who have a stenosis in at least one&#xD;
      major epicardial vessel confirmed by CCTA, who have undergone FFRCT analysis, and who are&#xD;
      scheduled to undergo clinically indicated IVUS-guided invasive evaluation and/or treatment&#xD;
      will be eligible for enrollment. Enrolling sites will have FFRCT analysis incorporated when&#xD;
      indicated into their standard evaluation of CCTA scans. Data collected will include CCTA and&#xD;
      FFRCT, full angiographic, and IVUS images, and if obtained, any other imaging or physiologic&#xD;
      data including OCT, FFR, any NHPR (e.g., dPR, RFR, iFR, etc.), and pre- and post-stent&#xD;
      implantation invasive data. All non-invasive and invasive data collected will be obtained as&#xD;
      clinical practice consistent with standard clinical care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>total plaque volume</measure>
    <time_frame>During IVUS procedure</time_frame>
    <description>Compare total plaque volume with IVUS obtained during ICA</description>
  </primary_outcome>
  <other_outcome>
    <measure>calcified plaque volume, plow attenuated plaque volume, fibrous plaque volume,</measure>
    <time_frame>During IVUS procedure</time_frame>
    <description>Compare with IVUS obtained during ICA</description>
  </other_outcome>
  <other_outcome>
    <measure>percent plaque burden,</measure>
    <time_frame>During IVUS procedure</time_frame>
    <description>Compare with IVUS obtained during ICA</description>
  </other_outcome>
  <other_outcome>
    <measure>minimum lumen area</measure>
    <time_frame>During IVUS procedure</time_frame>
    <description>Compare with IVUS obtained during ICA</description>
  </other_outcome>
  <other_outcome>
    <measure>positive remodeling index and percent area stenosis</measure>
    <time_frame>During IVUS procedure</time_frame>
    <description>Compare with IVUS obtained during ICA</description>
  </other_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Coronary Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Clinically stable patients with known CAD who have a CCTA showing stenosis in at least one&#xD;
        major epicardial vessel of stentable/graftable diameter and in whom clinically-indicated&#xD;
        IVUS is planned.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria (all must be present):&#xD;
&#xD;
          1. Age â‰¥18 years&#xD;
&#xD;
          2. Clinically stable patient with known CAD&#xD;
&#xD;
          3. CCTA showing stenosis in at least one major epicardial vessel of stentable/graftable&#xD;
             diameter, in whom clinically indicated IVUS is planned within 45 days of the CCTA and&#xD;
             FFRct available&#xD;
&#xD;
          4. FFRct successfully processed&#xD;
&#xD;
          5. Willing to comply with all aspects of the protocol&#xD;
&#xD;
          6. Agrees to be included in the study and able to provide written informed consent.&#xD;
&#xD;
        Exclusion criteria (all must be absent):&#xD;
&#xD;
          1. 1. CCTA showing no stenosis&#xD;
&#xD;
          2. Uninterpretable CCTA by HeartFlow assessment, in which image quality prevents FFRCT&#xD;
             from being processed.&#xD;
&#xD;
          3. Acute chest pain&#xD;
&#xD;
          4. CABG prior to CCTA acquisition&#xD;
&#xD;
          5. Prior history of PCI for 3 or more vessels&#xD;
&#xD;
          6. MI less than 30 days prior to CCTA or between CCTA and ICA.&#xD;
&#xD;
          7. Suspicion of acute coronary syndrome (acute myocardial infarction or unstable angina)&#xD;
&#xD;
          8. Known complex congenital heart disease&#xD;
&#xD;
          9. Tachycardia or significant arrhythmia&#xD;
&#xD;
         10. Subject requires an emergent procedure&#xD;
&#xD;
         11. Evidence of ongoing or active clinical instability, including acute chest pain (sudden&#xD;
             onset), cardiogenic shock, unstable blood pressure with systolic blood pressure &lt;90&#xD;
             mmHg, and severe congestive heart failure (NYHA III or IV) or acute pulmonary edema&#xD;
&#xD;
         12. Any active, serious, life-threatening disease with a life expectancy of less than 2&#xD;
             months&#xD;
&#xD;
         13. Currently enrolled in another study utilizing FFRCT or in an investigational trial&#xD;
             that involves a non-approved cardiac drug or device&#xD;
&#xD;
         14. Persons under the protection of justice, guardianship, or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jagat Narula, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HeartFlow Investigative Site</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Stuckey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HeartFlow Investigative site</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gaku Nakazawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HeartFlow investigative site</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Mullen</last_name>
    <phone>408.314.2335</phone>
    <email>smullen@heartflow.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saba Mirza</last_name>
    <phone>6508679419</phone>
    <email>smirza@heartflow.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HeartFlow Investigative Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Saalfeld, MBA</last_name>
      <phone>402-483-3294</phone>
      <email>rose.saalfeld@bryanheart.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

